About SAGE Therapeutics
SAGE Therapeutics is a Healthcare company based in Boston (United States) founded in 1971 by Vincent Foglia, and was acquired by Supernus Pharmaceuticals in June 2025. Developer of drug candidates for the treatment of rare CNS disorders. SAGE Therapeutics has raised $105.8 million across 6 funding rounds from investors including Bank of America, Supernus Pharmaceuticals and Orbimed. The company has 487 employees. Its chief executive, as recorded, is Vincent Foglia. Its focus areas include Life Sciences, Neurology, Drugs and Diversified. Its competitors include Boston Scientific, Medtronic and GE Healthcare; 1 of its 3 listed competitors has raised funding.
Company details
SAGE Therapeutics was founded in 1971 in Boston, United States, and focuses on the biotechnology sector. Drug candidates targeting GABAA and NMDA receptors are developed for rare central nervous system disorders, including those related to mood, seizure, cognition, anxiety, sleep, pain, epilepsy, and movement. A pipeline of products is maintained, with the lead candidate SAGE-547 intended for postpartum depression treatment. Operations emphasize therapeutic innovation in neurology.
- Headquarters Boston, United States
- Employees 487
- Founders Vincent Foglia
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website sagerx.com
- Social LinkedIn X Facebook Instagram
- Acquired by Supernus Pharmaceuticals (Jun 2025)
- Total Equity Funding$105.8M (USD)
in 6 rounds
- Latest Funding Round$649.99M (USD), Post-IPO
Jan 2021
- InvestorsBank of America
& 6 more
- Employee Count487
- Acquired bySupernus Pharmaceuticals
(Jun 2025)
Funding Insights of SAGE Therapeutics
SAGE Therapeutics has successfully raised a total of $105.8M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $649.99 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $105.8M
- Total Rounds 6
- Last Round Post-IPO — $649.99M
- First Round $37.8M
(Sep 2011)
- Investors Count 6
All 6 funding rounds of SAGE Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2021 | $649.99M | Post-IPO | – | – | – |
| Mar 2014 | $38M | Series C | – | Orbimed, Foresite Capital | |
| Jan 2014 | $10M | Series C | – | – | – |
| Oct 2013 | $20M | Series B | – | – | |
| Dec 2012 | Debt – Conventional | – | – | ||
| Sep 2011 | $37.8M | Series A | – | – |
7 investors in total: 7 institutional.
Investors in SAGE Therapeutics
SAGE Therapeutics has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Bank of America, Supernus Pharmaceuticals and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Multi-stage investment firm invests in healthcare and life sciences companies | foresitecapital.com | New York, United States | ||
Venture capital funding is provided to early-stage life science companies. | thirdrockventures.com | Boston, United States | ||
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
| ecor1cap.com | ||||
Commercial banking and asset management services are offered worldwide. | 1904 | bankofamerica.com | Charlotte, United States | |
Specialty pharmaceutical products for CNS diseases are developed and commercialized. | 2005 | supernus.com | Rockville, United States |
Investor details for SAGE Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of SAGE Therapeutics
87 people are tracked at SAGE Therapeutics (57 in leadership, 5 in board & advisors, 25 in team); the tracked headcount is 487.
| Name | Role | Group |
|---|---|---|
Vincent Foglia | Founder & CEO | Leadership |
Barry Greene | CEO | Leadership |
Kirsty Nahm M.D. Mrcp Mbbs | Medical Director, Medical Affairs | Leadership |
Barry E. Greene | CEO | Leadership |
Rac Elizabeth Keiper | Director, Regulatory Affairs | Leadership |
Sunil Chawla | Executive Director, Supply Chain | Leadership |
Ruta Sawant | Director | Leadership |
Sindhura Mogulla | Associate Director, Analytical Development And QC | Leadership |
Rebecca Coleman | Associate Director, Digital & Enterprise Capabilities Operations | Leadership |
Jeff Kasten | Vice President, Corporate Strategy & Business Development | Leadership |
Etchell Cordero | Executive Director, Business Operations | Leadership |
Vikas Tiwari | Senior Director - Data Science And Decision Analytics | Leadership |
Vera Richman | Director, National Payer Accounts | Leadership |
Steve Scarbrough | Senior Director Medical Affairs | Leadership |
Taryn Westerkamp | Associate Director, People & Experience | Leadership |
Matthew Henson | Vice President, Corporate Communications | Leadership |
Lisa Lopez | Vice President, Employee Communications And Experience | Leadership |
Stephanie Lamenta | Executive Director, Program & Commercial Communications | Leadership |
Robert A. | Senior Vice President, Strategic Insights/analytics, Field Effectiveness, Forecasting | Leadership |
Amanda Spear Hartley | Senior Director, Head Of Publications | Leadership |
67 more people are available in the full profile.
Complete people profiles for SAGE Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of SAGE Therapeutics
5 dated milestones of SAGE Therapeutics across 54 years, from founding to its latest funding, stage changes and deals.
- Founded SAGE Therapeutics is founded.
- Funding First funding round of $37.8M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $650.0M.
- Exit Acquired by Supernus Pharmaceuticals.
Competitors of SAGE Therapeutics
SAGE Therapeutics has 3 listed competitors in our database, 1 of them funded. They include Boston Scientific, Medtronic and GE Healthcare.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bostonscientific.com | 1979 | Marlborough, United States | 63,359 | Wide range of medical devices | ||
| medtronic.com | 1949 | Minneapolis, United States | 1,114 | Medical equipment for treating over 30 chronic diseases is developed. | ||
| gehealthcare.com | 1892 | Chicago, United States | $29.13M | 16,700 | Materials management solutions are provided for healthcare organizations. |
Detailed competitors of SAGE Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of SAGE Therapeutics
The website of SAGE Therapeutics (sagerx.com) receives about 8.4K visits a month and ranks #2,562,704 among all websites worldwide, #3,511 in Biotechnology and Pharmaceuticals.
- Monthly visits8.4K
▼ 7.8% vs previous month
- Unique visitors3.8K
per month
- Global rank#2,562,704
among all websites
- Category rank#3,511
Health · Biotechnology and Pharmaceuticals
- Bounce rate41%
- Pages per visit1.5
- Average visit7 sec
- DevicesDesktop 36% · Mobile 64%
Websites whose visitors overlap most with SAGE Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| alector.com | 100% | 6.1K | #3,370,379 | View details | |
| geneonline.com | 96% | 55.1K | #771,598 | View details | |
endpoints.news | endpoints.news | 95% | – | ||
| pharma-mkting.com | 87% | #2,044,310 | View details | ||
| lundbeck.com | 87% | 137.6K | #280,857 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for SAGE Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Diversified Medical Devices
3 companies that operate in the same segment as SAGE Therapeutics (Diversified Medical Devices) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medical equipment for treating over 30 chronic diseases is developed. | 1949 | Minneapolis, Minnesota, United States | USD 36.36 B | 95,000 | ||
Wide range of medical devices | 1979 | Marlborough, Massachusetts, United States | USD 20.07 B | 53,000 | ||
Healthcare solutions are provided by Johnson & Johnson globally. | 1886 | New Brunswick, New Jersey, United States | USD 94.18 B | 139,800 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sage Therapeutics
Complete news archive for SAGE Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SAGE Therapeutics
SAGE Therapeutics was founded in 1971 and raised its 1st funding round 40 years after it was founded.
SAGE Therapeutics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Vincent Foglia is the CEO of SAGE Therapeutics, as recorded in our data. They have also founded this company.
SAGE Therapeutics is a funded company, having raised a total of $105.8M across 6 funding rounds to date. The company's 1st funding round was a Series A of $37.8M, raised on Sep 2011.
SAGE Therapeutics has 487 employees.
SAGE Therapeutics was founded in 1971 in Boston, United States, and focuses on the biotechnology sector. Drug candidates targeting GABAA and NMDA receptors are developed for rare central nervous system disorders, including those related to mood, seizure, cognition, anxiety, sleep, pain, epilepsy, and movement. A pipeline of products is maintained, with the lead candidate SAGE-547 intended for postpartum depression treatment. Operations emphasize therapeutic innovation in neurology.
SAGE Therapeutics's top competitors include GE Healthcare, Medtronic and Boston Scientific.
SAGE Therapeutics has 7 investors. Key investors include Bank of America, Supernus Pharmaceuticals, Orbimed, Arch Venture Partners, and Foresite Capital.
Yes. SAGE Therapeutics was acquired by Supernus Pharmaceuticals in June 2025.